Table 2.
Treatment information
| Radiation therapy | Median | Min | Max |
|---|---|---|---|
| Reirradiation dose received (Gy) | 41.4 | 12.6 | 54.0 |
| Reirradiation volume (cm3) | 202 | 20 | 901 |
| Cumulative maximum brainstem dose (Gy) | |||
| All evaluable plansa | 76.9 | 5.0 | 108.3 |
| Composite onlyb | 67.9 | 5.0 | 99.5 |
| Cumulative maximum optic structure dose (Gy) | |||
| All evaluable plans | 56.0 | 4.5 | 90.9 |
| Composite only | 55.6 | 4.5 | 90.9 |
| Time from initial to repeat radiation (mos) | 27.6 | 4.8 | 214.2 |
| Concurrent systemic therapy | Number | % |
|---|---|---|
| Temozolomide | 66 | 55.9 |
| Bevacizumab | 16 | 13.6 |
| Temozolomide+bevacizumab | 13 | 11.0 |
| Other | 1 | 0.8 |
| None | 22 | 18.6 |
Cumulative maximum brainstem and optic structure doses are reported for:
a
All patients with plan information from initial and reirradiation treatments (summation of maximum point doses anywhere in the structure when composite plan fusion not available) (n = 69).
b
Patients with composite plan fusions only (n = 41).